Effective 4/15/2026, Cigna updated Medical Coverage Policy 0558 (MDC 05: Cardiology & Vascular) to designate a broad set of Category III CPT codes as Experimental/Investigational/Unproven, including cardiovascular-specific codes such as 0439T (myocardial contrast perfusion echocardiography) and 0525T (intracardiac ischemia monitoring system insertion/replacement). The revision lists multiple transcatheter and intracardiac procedures (for example, 0338T/0339T renal denervation, 0644T intracardiac mass debulking, 0659T intracoronary supersaturated oxygen) with procedural descriptions highlighting imaging and device components. Related Coverage Resources were updated to cross-reference other Cigna and eviCore policies (ambulatory external/implantable ECG monitoring, adult/pediatric cardiac imaging, transcatheter heart valve procedures), and the policy notes that some Category III codes are treated as medically necessary in other Cigna or eviCore resources. Providers should review the effective-dated list before billing or requesting authorization for these Category III services given the experimental/unproven designation.
April 2026 Revision: Effective Date and Experimental/Investigational Code Designations
This revision is effective 4/15/2026 for Cigna Medical Coverage Policy 0558 within MDC 05: Cardiology & Vascular (Heart/Circulatory). The document lists a set of Category III CPT codes explicitly considered "Experimental/Investigational/Unproven," including several cardiovascular and cardiac-related Category III codes such as 0439T (myocardial contrast perfusion echocardiography) and 0525T (insertion or replacement of intracardiac ischemia monitoring system). The effective-date heading is repeated multiple times in the source, reinforcing that the experimental/unproven code designations are tied to the 4/15/2026 effective date.
The revision also updates the Related Coverage Resources and cross-references to other Cigna policies and eviCore guidelines relevant to cardio-vascular imaging and monitoring (for example, Ambulatory External and Implantable Electrocardiographic Monitoring and Transcatheter Heart Valve Procedures). Additionally, several new or enumerated Category III codes across multiple anatomic areas and device types are listed as considered experimental/investigational in this effective-dated release.
Category III Codes Marked Experimental/Investigational — Cardiac Imaging and Monitoring
The policy identifies a broad list of Category III CPT codes designated as "Experimental/Investigational/Unproven." Cardiovascular-relevant entries in that list include 0338T and (transcatheter renal sympathetic denervation, unilateral and bilateral), (myocardial contrast perfusion echocardiography), (intracardiac ischemia monitoring system insertion/replacement), (transcatheter removal or debulking of intracardiac mass), and (transcatheter intracoronary infusion of supersaturated oxygen during acute MI), among others. These codes are grouped with many non-cardiac Category III codes in the same experimental/unproven listing.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.